REVISTA ROMÂNĂ DE GERONTOLOGIE ȘI GERIATRIE - VOLUMUL 2
ÎN ACEST NUMĂR ESTE 1 ARTICOL
Theoritical bases of procaine therapy (Gerovital H3 and Aslavital) in the prophylaxis of aging
1981, Volumul 2, Numărul 1, Paginile
Summary. The reduced number and functional capacities of the cells during the aging process induces numerous characteristics of aging. As regards the neurons, the main object is to extend the cellular resources, with the help of the psycho-pharmacology. The author proved, 25 years ago, the influence of procaine on the nervous system, by psychological and functional, clinical and experimental investigations. Recently the procaine pharmacology has developed by means of some American authors' researches, among which double-blind studies, concerning the favourable effect of Gerovital H3 on the depressive moods of the elderly. The connection was proved between the aging process and the the intesification of mono-aminoxidase activity in the brain as well as procaine and especially Gerovital H3 capacity to inhibit MAO and to reduce the aging marks at the level of the central nervous system. The anabolic action of procaine was proved in researches on cell cultures as well as on the animal finding, among others, an improved general trophicity and a prolonged life span. Other results obtained in the field of procaine action mechanisms refer to: the improved nitrogenous balance, favoured ATP synthesis, antioxidating action, intervention in the oxidative phosphorylation, the fat metabolism disturbances of athrosclerosis, the inceased speed of nerve condition, the excretion of urinary steroids and metabolites, etc. The ultrastructural studies revealed the contribution of Gerovital H3 to the stabilization of membranes and of the main cellular organelles, the intensification of cell metabolic activity in the treated cultures. All these lie at the basis of the prophylactic action and therapy of the aging phenomenon. In order to intensify the lipotropic action as well as that on the cerebral aging, the author elaborated a new product, Aslavital. The result of the treatment obtained in the first 9 years of application prove its efficacy in the involutive processes, predominantly cerebral, and in artherosclerosis (especially in the disorders of blood coagulability and lipid metabolism) as well as in the prevention of treatment of complications.
